Viriom Inc., dedicated to advancing a pipeline of highly effective and broadly affordable treatments targeting infectious and malignant diseases globally, announces the successful completion and positive results of Phase I clinical trial for AV5124, a novel inhibitor of influenza virus replication. AV5124 is an extremely effective inhibitor of influenza virus RNA processing that is potent against all tested influenza types including viruses resistant to neuraminidase inhibitors (Tamiflu®) or cap-dependent endonuclease inhibitors (Zoflusa®).
The recently concluded Phase I clinical studies demonstrated remarkable safety and tolerability of AV5124. Blood drug levels achieved in this study are consistent with potent virus suppression for several days after a single oral exposure. The excellent safety profile and known potency of AV5124 against influenza virus supports advancing this compound into Phase II-III efficacy studies that will begin during this year’s influenza season.
Laboratory studies supporting the development of AV5124 showed extremely potent suppression of all tested Influenza A and Influenza B viruses, including drug-resistant variants. AV5124 is also a potent inhibitor of highly pathogenic avian influenza viruses circulating in nature, indicating the potential for seasonal or pandemic influenza treatment, and for pandemic preparedness. This advance in the development of influenza virus therapy underscores Viriom’s dedication to advancing treatments that address the evolving challenges of influenza and other infectious or malignant diseases.
